Related Experiment Video
Updated: May 14, 2026
Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
Published on: June 8, 2019
Circulating Tumor DNA in Cholangiocarcinoma: A Precision Oncology Roadmap
Haixing Wei1, Jie Wang1, Qing Wu1
1Department of Gastroenterology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530007, People's Republic of China.
Abstract:
Cholangiocarcinoma (CCA) is a rare but aggressive malignancy with a rising global incidence and few therapeutic options for advanced disease. In recent decades, precision oncology for CCA has advanced rapidly, particularly through the development of targeted therapies for patients with actionable genetic alterations. These therapies have markedly prolonged survival and improved other clinical outcomes among patients with unresectable, advanced CCA. The implementation of precision oncology largely depends on detecting genetic mutations to guide patient selection and treatment, using tumor tissue biopsies or liquid biopsies, including circulating tumor DNA (ctDNA) from blood or bile. As a minimally invasive biomarker, ctDNA shows great promise for transforming the clinical management of CCA. This review provides a comprehensive overview of the roles of ctDNA in CCA, including early detection, prognostic stratification, minimal residual disease assessment, recurrence monitoring, therapeutic target identification, and treatment response evaluation. A synthesis of existing studies indicates that bile-derived ctDNA shows superior sensitivity compared with blood-based ctDNA in capturing the genetic profiles and heterogeneity of CCA. We also propose an integrative framework that illustrates how ctDNA profiling can inform diagnosis, treatment, and surveillance across the disease continuum. Because research on ctDNA in CCA remains in its infancy, we discuss current challenges and outline future directions for translating these findings into clinical practice. Collectively, the evidence positions ctDNA-particularly bile-derived ctDNA-as a dynamic tool for real-time genomic profiling, sensitive residual disease detection, and therapy monitoring. This integrative framework provides a roadmap for translating these capabilities into clinical practice, with the potential to enable earlier, more personalized interventions and improve outcomes for patients with CCA.
Insights
Circulating tumor DNA (ctDNA) shows promise for managing cholangiocarcinoma (CCA). Bile-derived ctDNA is more sensitive than blood-based ctDNA for detecting genetic mutations and monitoring treatment response in CCA patients.
Area of Science:
- Oncology
- Genetics
- Biomarkers
Background:
- Cholangiocarcinoma (CCA) is an aggressive cancer with limited treatment options.
- Precision oncology has advanced CCA treatment through targeted therapies.
- Accurate genetic mutation detection is crucial for guiding CCA treatment.
Purpose of the Study:
- To review the multifaceted roles of circulating tumor DNA (ctDNA) in cholangiocarcinoma (CCA) management.
- To evaluate ctDNA's potential in early detection, prognosis, and monitoring treatment response.
- To propose a framework for integrating ctDNA into clinical practice for CCA.
Main Methods:
- Comprehensive review of existing studies on ctDNA in CCA.
- Comparison of blood-based versus bile-derived ctDNA sensitivity.
- Synthesis of evidence for ctDNA applications across the CCA disease continuum.
Main Results:
- ctDNA is a promising minimally invasive biomarker for CCA.
- Bile-derived ctDNA demonstrates superior sensitivity over blood-based ctDNA for CCA.
- ctDNA aids in early detection, prognostic stratification, and monitoring minimal residual disease.
Conclusions:
- ctDNA, especially bile-derived, is a dynamic tool for real-time genomic profiling in CCA.
- ctDNA profiling can inform diagnosis, treatment, and surveillance for CCA.
- Further research is needed to translate ctDNA findings into clinical practice for improved CCA patient outcomes.
